Short Interest Don’t Lie: It Seems Tokai Pharmaceuticals Incorporated (NASDAQ:TKAI) Will Go Down. Just Reported More Shorted Shares

November 17, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Don't Lie: It Seems Tokai Pharmaceuticals Incorporated (NASDAQ:TKAI) Will Go Down. Just Reported More Shorted Shares

The stock of Tokai Pharmaceuticals Incorporated (NASDAQ:TKAI) registered an increase of 0.12% in short interest. TKAI’s total short interest was 493,800 shares in November as published by FINRA. Its up 0.12% from 493,200 shares, reported previously. With 1.15 million shares average volume, it will take short sellers 0 days to cover their TKAI’s short positions. The short interest to Tokai Pharmaceuticals Incorporated’s float is 6.18%. About 477,686 shares traded hands. Tokai Pharmaceuticals Inc (NASDAQ:TKAI) has declined 84.12% since April 15, 2016 and is downtrending. It has underperformed by 88.74% the S&P500.

Tokai Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $28.71 million. The Firm is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. It currently has negative earnings. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

Insitutional Activity: The institutional sentiment decreased to 0.88 in Q2 2016. Its down 0.26, from 1.14 in 2016Q1. The ratio turned negative, as 6 funds sold all Tokai Pharmaceuticals Inc shares owned while 18 reduced positions. 3 funds bought stakes while 18 increased positions. They now own 5.38 million shares or 6.48% less from 5.76 million shares in 2016Q1.
Novo A S last reported 128,993 shares in the company. Franklin Res Inc, a California-based fund reported 475,600 shares. The Massachusetts-based Putnam Investments Ltd Liability has invested 0% in Tokai Pharmaceuticals Inc (NASDAQ:TKAI). Bnp Paribas Arbitrage accumulated 397 shares or 0% of the stock. Senzar Asset Llc reported 511,010 shares or 0% of all its holdings. Moreover, Blackrock Mngmt Lc has 0% invested in Tokai Pharmaceuticals Inc (NASDAQ:TKAI) for 33,761 shares. Vanguard accumulated 256,582 shares or 0% of the stock. Nationwide Fund reported 6,088 shares or 0% of all its holdings. Deutsche Bancshares Ag last reported 47,847 shares in the company. Jpmorgan Chase Co holds 97,442 shares or 0% of its portfolio. Geode Mngmt Ltd Liability, a Massachusetts-based fund reported 57,977 shares. Retail Bank Of Montreal Can accumulated 0% or 16 shares. Group holds 5,706 shares or 0% of its portfolio. Fmr Lc owns 532,700 shares or 0% of their US portfolio. Blackrock accumulated 0% or 635 shares.

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) Ratings Coverage

Out of 5 analysts covering Tokai Pharmaceuticals (NASDAQ:TKAI), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Tokai Pharmaceuticals has been the topic of 8 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Zacks upgraded the shares of TKAI in a report on Tuesday, August 18 to “Hold” rating. The firm earned “Neutral” rating on Tuesday, July 26 by Janney Capital. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Outperform”. On Thursday, February 11 the stock rating was initiated by Oppenheimer with “Outperform”. The stock of Tokai Pharmaceuticals Inc (NASDAQ:TKAI) has “Market Perform” rating given on Tuesday, July 26 by Wells Fargo. The firm has “Buy” rating by Bank of America given on Wednesday, April 6. The firm has “Buy” rating by Janney Capital given on Thursday, April 7. Wells Fargo initiated the shares of TKAI in a report on Friday, December 4 with “Outperform” rating.

TKAI Company Profile

Tokai Pharmaceuticals, Inc., incorporated on March 26, 2004, is a biopharmaceutical company. The Firm is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation. The Firm develops galeterone for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC.

More news for Tokai Pharmaceuticals Inc (NASDAQ:TKAI) were recently published by: Marketwatch.com, which released: “Tokai Pharmaceuticals stock plummets after drug trial discontinued” on July 26, 2016. Prnewswire.com‘s article titled: “WeissLaw LLP Announces Class Action Lawsuit Against Tokai Pharmaceuticals, Inc.” and published on September 15, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>